AUTHORS
Aikaterini Mallou, Uday Aditya Sarkar, PhD2, Konstantina Zampouridou3, Athina Tziogkidou4, Anastasia Anastasiadou5, Konstantinos Kardamiliotis6, Anastasia Iatrou7, Andreas Agathangelidis8, Fotis Psomopoulos9, Zachary R Hunter, PhD10, Anastasia Chatzidimitriou11, Paolo Ghia, MD, PhD12, Steven Treon, MD, PhD13, Kostas Stamatopoulos, MD, PhD14
AFFILIATIONS
1 Centre for Research and Technology Hellas, Thessaloniki, Greece, National and Kapodistrian University of Athens, Athens, Greece
3 Centre for Research and Technology Hellas, Thessaloniki, Greece
4 Centre for Research and Technology Hellas, Thessaloniki, Greece
5 Centre for Research and Technology Hellas, Thessaloniki, Greece
6 Centre for Research and Technology Hellas, Thessaloniki, Greece, National and Kapodistrian University of Athens, Athens, Greece
7 Centre for Research and Technology Hellas, Thessaloniki, Greece, Karolinska Institutet, Stockholm, Sweden
8 National and Kapodistrian University of Athens, Athens, Greece
9 Centre for Research and Technology Hellas, Thessaloniki, Greece
10 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
11 Centre for Research and Technology Hellas, Thessaloniki, Greece, Karolinska Institutet, Stockholm, Sweden
12 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, IRCCS Ospedale San Raffaele, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy
13 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
14 Centre for Research and Technology Hellas, Thessaloniki, Greece, Karolinska Institutet, Stockholm, Sweden
ABSTRACT
Background
Waldenström’s macroglobulinemia (WM) is an IgM-secreting B-cell lymphoma, associated with bone marrow (BM) infiltration by lymphoplasmacytic cells. WM is defined by recurrent mutations in MYD88, detected in most cases, while retaining substantial biological heterogeneity, reflected along the B-cell to plasma-cell differentiation axis. Among the MYD88-mutated cases, two major disease subgroups have been identified: the B-cell-like subtype (BCL) and the plasma-cell-like subtype (PCL). The first displays features of CD19?CD27? memory B cells, whereas the latter resembles IgM multiple myeloma. In addition to the two divergent states, an intermediate disease state, namely Early WM (EWM), has been proposed to represent an earlier phase of disease development, from which both BCL and PCL trajectories subsequently emerge.
Aims
Previous studies, largely based on low-throughput approaches, have revealed biased IGHV gene usage and extensive somatic hypermutation (SHM) in WM. However, the immunogenetic architecture of B-cell receptor immunoglobulin (BcR IG) gene repertoire, as shaped by the affinity maturation, remains insufficiently understood. This is the focus of the present study.
Methods
We analyzed 77 cases with WM, including 29 BCL, 25 PCL, 23 EWM. Genomic DNA isolated from BM mononuclear cells was used for PCR amplification of IGHV-IGHD-IGHJ gene rearrangements, followed by paired-end NGS of the resulting amplicons. Sequence annotation and downstream immunogenetic analysis were performed with IMGT/High V-QUEST and tripR, respectively. Matched RNA-sequencing data were subsequently used for immune repertoire reconstruction with TRUST4.
Results
Clonality assessment classified 60/77 (77.9%) cases as monoclonal. A dominant clonotype embedded within a polyclonal background was detected in 11/77 (14.3%) cases, while 6/77 (7.8%) cases harbored two major clones. Clonality patterns varied across disease subtypes: oligo/polyclonal profiles occurred more frequently in EWM (8/23 vs 3/29 BCL vs 1/25 PCL cases; p<0.05), perhaps reflecting a lower degree of BM infiltration at this earlier stage of disease evolution. IGHV3 subgroup genes predominated amongst the dominant clonotypes (57/77 cases; 74%). The skewing was largely driven by 4 genes, namely IGHV3-23 (n=13), IGHV3-74 (n=12), IGHV3-7 (n=11) and IGHV3-30 (n=11), collectively comprising 61% of the dominant clonotypes. Subtype-specific differences were also present: PCL showed a bias to IGHV3-23 (7/25 cases; 28%), BCL displayed a less restricted IGHV gene repertoire, while EWM showed an enrichment for the IGHV4-34 gene (5/23; 21.7%). Restricted heavy-light chain (HC, LC) pairing was observed for the IGHV3-74 gene which often (5/12 cases; 41.7%) paired with the IGKV2-28/2D-28 gene. In all cases, the major HC clonotype was somatically hypermutated (IGHV gene identity: 87.85-97.92%; median: 93.43%) and extensively diversified, in the sense of an ecosystem of cells with different SHM status and HC isotype. Further analysis of SHM patterns across the most frequently used IGHV genes revealed non-random targeting of specific positions, including recurrent mutations shared among unrelated patients. The dominant LC rearrangements were also mutated in most cases, albeit with a less pronounced SHM burden (IGKV/IGLV gene identity: 89.38-99.31%; median: 96.47%). Notably, low-frequency clonally related rearrangements retaining 100% germline identity were identified in 57% of cases, implying extensive ID within the malignant clone. Moreover, although all detected dominant clonotypes were of the mu isotype, clonally related gamma and/or alpha transcripts were identified in 56% of cases indicating that class switch recombination occurs within the malignant clone leading to ID. Both aforementioned features i.e. clonally related unmutated clonotypes and switched clonotypic IGHV-IGHD-IGHJ transcripts co-occurred in 27/77 cases (35%).
Discussion
WM exhibits pronounced ID together with recurrent SHM patterns, consistent with convergent, antigen-driven shaping of the BcR repertoire and ongoing adaptation of the malignant clone. The distinct immunogenetic and transcriptomic features observed across disease subtypes indicate distinct evolutionary routes linked to divergent differentiation trajectories.
DISCLOSURES
Aikaterini Mallou: No relevant conflicts of interest to declare.